Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms
Bin Wang,Yin Han,Yuyu Zhang,Qin Zhao,Huanhuan Wang,Jinlong Wei,Lingbin Meng,Ying Xin,Xin Jiang
DOI: https://doi.org/10.1186/s13578-023-01073-9
2023-06-30
Abstract:Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 to boost tumor-specific T lymphocyte immunity have opened up new avenues for the treatment of various histological types of malignancies, with the possibility of durable responses and improved survival. However, the development of acquired resistance to ICI therapy over time after an initial response remains a major obstacle in cancer therapeutics. The potential mechanisms of acquired resistance to ICI therapy are still ambiguous. In this review, we focused on the current understanding of the mechanisms of acquired resistance to ICIs, including the lack of neoantigens and effective antigen presentation, mutations of IFN‐γ/JAK signaling, and activation of alternate inhibitory immune checkpoints, immunosuppressive tumor microenvironment, epigenetic modification, and dysbiosis of the gut microbiome. Further, based on these mechanisms, potential therapeutic strategies to reverse the resistance to ICIs, which could provide clinical benefits to cancer patients, are also briefly discussed.
biochemistry & molecular biology